CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 44 enrolled
Drug / intervention
dexamethasone +1 moredrug
Likely dose
dexamethasone 700 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00775411
NCT00775411Phase 2Completed
CompareCT.gov

Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)

Allergan·interventional·Posted Oct 20, 2008·Updated Sep 3, 2012

In Brief

A Phase 2 clinical trial evaluating dexamethasone and ranibizumab for Choroidal Neovascularization and Age-Related Maculopathy. Completed, enrolled 44 participants across 3 sites in 3 countries.

Detailed Summary

The study will evaluate the safety and efficacy of the intravitreal dexamethasone implant as adjunctive therapy to Anti-VEGF treatment in the study eye of treatment naïve subjects with choroidal neovascularization secondary to age-related macular degeneration. Subjects will be followed for 26 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChoroidal Neovascularization, Age-Related Maculopathy
CountriesAustralia, Philippines, United States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 20, 2008
Enrollment StartNov 1, 2008
Primary CompletionNov 1, 2009
Study CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 17.7 years ago

Interventions

dexamethasonedrug

700 µg dexamethasone intravitreal injection at Day 1 in the study eye.

ranibizumabbiological

Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion in the study eye.